Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read More
Tag: ofatumumab
Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More
Regulators expand review time for Novartis’ MS drug
Regulatory action is now expected in September 2020
Read More
- Researchers reveal how a protein interaction can increase Alzheimer’s risk
- Scientists uncover new disease-driving mechanism to treat atheroschlerosis
- Study shows cholesterol-lowering drug reduces diabetic retinopathy risk
- UK dementia organisations publish new manifesto ahead of general election
- Europe contributes over €750m to African Vaccines Manufacturing Accelerator
